Trevi Therapeutics, Inc. Total Liabilities
Trevi Therapeutics, Inc. (TRVI) had Total Liabilities of $9.01 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-06
- 2026-06-30: Liabilities $9.01M.
- 2026-03-31: Liabilities $7.48M.
- 2025-12-31: Liabilities $10.20M.
- 2025-09-30: Liabilities $9.57M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $9.01M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $7.48M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $10.20M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $9.57M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $9.85M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $7.55M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $11.26M 10-K · filed 2026-03-17 |
| 2024-09-30 | $9.94M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $7.64M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $6.22M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $6.86M 10-K · filed 2025-03-18 |
| 2023-09-30 | $6.29M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $5.90M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $14.47M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $15.56M 10-K · filed 2024-03-20 |
| 2022-09-30 | $18.46M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $20.90M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $19.92M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $21.40M 10-K · filed 2023-03-16 |
| 2021-09-30 | $20.22M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $21.41M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $19.18M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $19.85M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |